Strain HY701 was isolated from human feces for probiotic use by selecting highly resistant isolates to artificial gastric acid and bile acid. Strain HY701 was identified as Lactobacillus reuteri using 16S rDNA sequencing, and tentatively named L. reuteri HY701. The resistance of L. reuteri HY701 to artificial gastric acid (PH 2.5) was high with a survival rate of over 90%. L. reuteri HY701 also showed high tolerance to artificial bile acid after incubation in artificial gastric acid. Using the API ZYM test kit, the carcinogenic enzymes (${eta}$-glucuronidase and (${eta}$-glucosidase were not detected with L. reuteri HY70l, while the beneficial enzyme (${eta}$-galactosidase was weakly detected. L. reuteri HY701 was sensitive to $100;{mu}g/mL$ nisin, $20;{mu}g/mL$ roxithromycin, $15;{mu}g/mL$ erythromycin, but resistant to $20;{mu}g/mL$ streptomycin, $10;{mu}g/mL$ tetracycline, $20;{mu}g/mL$ ciprofloxacin, $20;{mu}g/mL$ nystatin, $20;{mu}g/mL$ gentamycin, $10;{mu}g/mL$ doxycycline, $10;{mu}g/mL$ chloramphenicol, and $20;{mu}g/mL$ ampicillin. L. reuteri HY701 was shown to possess bactericidal activity as it inhibited the growth of Listeria monocytogenes ATCC 19111 and Escherichia coli JM109 completely within 24 hr of incubation. These results indicate that L. reuteri HY701 could be used as a probiotic strain.